Feng Wang

Feng Wang

Auto-generated profile, based on publicly available information

Feng Wang

Novartis Biomedical Research

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2022 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
NHNathaniel J. Henning
Nathaniel J. Henning
LBLydia Boike
Lydia Boike
JSJessica N. Spradlin
Jessica N. Spradlin
CWCarl C. Ward
Carl C. Ward
GLGang Liu
Gang Liu
DNDaniel K. Nomura
Daniel K. Nomura

11 January 2013 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
FWFeng Wang
Feng Wang
CMChristopher Marshall
Christopher Marshall
MIMitsuhiko Ikura
Mitsuhiko Ikura

1 March 2019 in Cell Reports
Verified
Journal Article
Open access
EAErin R. Aho
Erin R. Aho
JWJing Wang
Jing Wang
RGRocco D. Gogliotti
Rocco D. Gogliotti
GHGregory C. Howard
Gregory C. Howard
JPJason Phan
Jason Phan
WTWilliam Tansey
William Tansey
The chromatin-associated protein WDR5 is a promising target for pharmacological inhibition in cancer. Drug discovery efforts center on the blockade of the "WIN site" of WDR5, a well-defined pocket that is amenable to small molecule inhibition. Various cancer contexts have been proposed to be targets for WIN site inhibitors, but a lack of understanding of WDR5 target genes and of the primary effects of WIN site inhibitors hampers their utility. Here, by the discovery of potent WIN site inhibitors, we demonstrate that the WIN site links WDR5 to chromatin at a small cohort of loci, including a specific subset of ribosome protein genes. WIN site inhibitors rapidly displace WDR5 from chromatin and decrease the expression of associated genes, causing translational inhibition, nucleolar stress, and p53 induction. Our studies define a mode by which WDR5 engages chromatin and forecast that WIN site blockade could have utility against multiple cancer types.

2 April 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
FWFeng Wang
Feng Wang
CMChristopher Marshall
Christopher Marshall
KYKazuo Yamamoto
Kazuo Yamamoto
GLGuang-Yao Li
Guang-Yao Li
GGGeneviève M. C. Gasmi-Seabrook
Geneviève M. C. Gasmi-Seabrook
MIMitsuhiko Ikura
Mitsuhiko Ikura
Forkhead box class O 3a (FOXO3a) is a transcription factor and tumor suppressor linked to longevity that determines cell fate through activating transcription of cell differentiation, survival, and apoptotic genes. Recruitment of the coactivator CBP/p300 is a crucial step in transcription, and we revealed that in addition to conserved region 3 (CR3) of FOXO3a, the C-terminal segment of CR2 (CR2C) binds CBP/p300 and contributes to transcriptional activity. CR2C and CR3 of FOXO3a interact with the KIX domain of CBP/p300 at both “MLL” and “c-Myb” binding sites simultaneously. A FOXO3a CR2C-CR3 peptide in complex with KIX exists in equilibrium between two equally populated conformational states, one of which has CR2C bound to the MLL site and CR3 bound to the c-Myb site, whereas in the other, CR2C and CR3 bind the c-Myb and MLL sites, respectively. This promiscuous interaction between FOXO3a and CBP/p300 is further supported by additional binding sites on CBP/p300, namely, the TAZ1 and TAZ2 domains. In functional studies, our structure-guided mutagenesis showed that both CR2C and CR3 are involved in the activation of certain endogenous FOXO3a target genes. Further, phosphorylation of S626, a known AMP-dependent protein kinase target in CR3, increased affinity for CBP/p300 and the phosphomimetic mutation enhanced transactivation of luciferase. These findings underscore the significance of promiscuous multivalent interactions and posttranslational modification in the recruitment of transcriptional coactivators, which may allow transcription factors to adapt to various gene-specific genomic and chromatin structures and respond to cell signals.

1 December 2008 in Journal of Molecular Biology
Verified
Journal Article
Closed access
FWFeng Wang
Feng Wang
CMChristopher Marshall
Christopher Marshall
KYKazuo Yamamoto
Kazuo Yamamoto
GLGuang-Yao Li
Guang-Yao Li
MPMichael J. Plevin
Michael J. Plevin
MIMitsuhiko Ikura
Mitsuhiko Ikura

3 February 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SMStephanie Anne Moquin
Stephanie Anne Moquin
OSOliver Simon
Oliver Simon
RKRatna Karuna
Ratna Karuna
SLSuresh B. Lakshminarayana
Suresh B. Lakshminarayana
FYFumiaki Yokokawa
Fumiaki Yokokawa
FGFeng Gu
Feng Gu
NITD-688, a pan-serotype dengue virus inhibitor, is effective in mice and is well tolerated with favorable pharmacokinetics in animal models.